Cargando…

Cost-Effectiveness Analysis of Antithyroid Drug (Propylthiouracil) Compared to Radioactive Iodine for the Treatment of Graves’ Disease in Ethiopia

BACKGROUND: Graves’ disease is an autoimmune disorder caused by stimulating antibodies. The peak incidence of Graves’ disease occurs among patients aged 30 to 60 years. Radioactive iodine (RAI) and antithyroid drug (ATD) have been well-established therapies for the treatment of Graves’ disease for s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mengistu, Habtamu Solomon, Getahun, Kidus Tesfaye, Alemayehu, Lake, Gezahign, Sifrash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012309/ https://www.ncbi.nlm.nih.gov/pubmed/35431562 http://dx.doi.org/10.2147/CEOR.S350984

Ejemplares similares

Duration of antithyroid drug treatment may predict weight gain after radioactive iodine therapy in patients with Graves’ disease
por: Yotsapon, Thewjitcharoen, et al.
Publicado: (2022)

Serum TNF-α in psoriasis after treatment with propylthiouracil, an antithyroid thioureylene
por: Elias, Alan N, et al.
Publicado: (2004)

Mode of binding of the antithyroid drug propylthiouracil to mammalian haem peroxidases. Erratum
por: Singh, R. P., et al.
Publicado: (2015)

CD1a expression in psoriatic skin following treatment with propylthiouracil, an antithyroid thioureylene
por: Elias, Alan N, et al.
Publicado: (2003)

Association of Radioactive Iodine, Antithyroid Drug, and Surgical Treatments With Solid Cancer Mortality in Patients With Hyperthyroidism
por: Kitahara, Cari M., et al.
Publicado: (2020)

Antithyroid Drug Treatment in Graves’ Disease
por: Chung, Jae Hoon
Publicado: (2021)

Pediatric Graves’ disease: management in the post-propylthiouracil Era
por: Rivkees, Scott A
Publicado: (2014)

Change in BMI after radioactive iodine ablation for graves disease
por: Chen, Melinda, et al.
Publicado: (2017)

Clinical Outcomes of Repeated Radioactive Iodine Therapy for Graves’ Disease
por: Kim, Min Joo, et al.
Publicado: (2022)

Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence
por: Liu, Jia, et al.
Publicado: (2017)

A CASE OF AUTOIMMUNE HEPATITIS WITH GRAVES’ DISEASE TREATED BY PROPYLTHIOURACIL
por: SATO, IKUKO, et al.
Publicado: (2011)

Clinical experience with radioactive iodine in the treatment of childhood and adolescent Graves' disease
por: Cury, Adriano N, et al.
Publicado: (2012)

Anaplastic Thyroid Carcinoma Following Radioactive Iodine Therapy for Graves' Disease
por: Kim, Sun Hwa, et al.
Publicado: (2013)

Chylothorax Associated with Substernal Goiter in Graves’ Disease Treated with Radioactive Iodine
por: Young Oh, Seo, et al.
Publicado: (2017)

Graves' Disease-Related Pancytopenia Improved after Radioactive Iodine Ablation
por: Hamid, Omnia A., et al.
Publicado: (2020)

Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves’ disease
por: Ze, Yuyang, et al.
Publicado: (2022)

Association between radioactive iodine uptake and neutropenia in untreated Graves’ disease
por: Yang, Qian, et al.
Publicado: (2023)

Investigating Antithyroid Effects of Propylthiouracil on the Ischemia and Reperfusion Injury in Rat’ Kidney and Determining the Role of Nitric Oxide in Mediating this Effect
por: Tofangchiha, Shahnaz, et al.
Publicado: (2014)

Antithyroid drugs in Graves’ disease: Are we stretching it too far?
por: Jayaraman, Muthukrishnan, et al.
Publicado: (2016)

Antithyroid Drugs in the Management of Graves' Disease: A Friend and Foe
por: Butt, Muhammad I, et al.
Publicado: (2023)

Prediction for recurrence following antithyroid drug therapy for Graves’ hyperthyroidism
por: Weng, Huan, et al.
Publicado: (2023)

Effect of iodine nutritional status on the recurrence of hyperthyroidism and antithyroid drug efficacy in adult patients with Graves’ disease: a systemic review
por: Xie, Qingxing, et al.
Publicado: (2023)

The Effects of Propylthiouracil and Thyrotropic Hormone on the Uptake of Radioactive Thallium by the Rat Thyroid
por: Ulrich, Frank, et al.
Publicado: (1955)

Thyroid Isthmus Length and Iodine Turnover as Predictors of Successful Radioactive Iodine Therapy in Patients with Graves' Disease
por: Park, Se Hee, et al.
Publicado: (2017)

Acute psychosis caused by hypothyroidism following radioactive iodine treatment of Graves' disease
por: Hyams, Catherine, et al.
Publicado: (2013)

Thyroid storm following radioactive iodine (RAI) therapy for pediatric graves disease
por: Rohrs, Henry J., et al.
Publicado: (2014)

A Case for Lithium Pretreatment Prior to Radioactive Iodine Ablation in Grave’s Disease
por: Thakkar, Aditi, et al.
Publicado: (2021)

FRI494 Ischemic Stroke After Radioactive Iodine Therapy In Graves Disease
por: Rave, Talia, et al.
Publicado: (2023)

Treatment of Graves’ Disease With a Combination of Low Iodine Diet and Potassium Iodide Plus Radioactive Iodine Treatment
por: Ebrahim, Ismail, et al.
Publicado: (2021)

Indefinite antithyroid drug therapy in toxic Graves’ disease: What are the cons
por: Rajput, Rajesh, et al.
Publicado: (2013)

Antithyroid treatment improves thrombocytopenia in a young patient with Graves’ disease
por: Faienza, Maria Felicia, et al.
Publicado: (2020)

Risk Factors for Granulocytopenia in Patients with Graves' Disease Receiving Antithyroid Drugs
por: Li, Jiaxi, et al.
Publicado: (2023)

Antithyroid arthritis syndrome caused by methimazole in a patient with Graves’ disease
por: Kawasumi, Muneo, et al.
Publicado: (2023)

The assessment of radio-adaptive response in graves' hyperthyroidism patients following radioactive iodine uptake
por: Fazeli, Zahra, et al.
Publicado: (2018)

Predictive factors for the outcomes of Graves’ disease patients with radioactive iodine ((131)I) treatment
por: Xing, Yu-Zhuo, et al.
Publicado: (2020)

Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves’ disease patients
por: Hu, Rui-Ting, et al.
Publicado: (2020)

Block and replace therapy using propylthiouracil and levothyroxine for Graves’ disease during pregnancy
por: Gupta, Vishal
Publicado: (2012)

Management of a Pregnant Patient with Graves' Disease Complicated by Propylthiouracil induced Agranulocytosis
por: Cho, Yoon-Young, et al.
Publicado: (2005)

Therapy with propylthiouracil for T3-predominant neonatal Graves’ disease: a case report
por: Hamajima, Emi, et al.
Publicado: (2018)

Biologically-Guided Isolation of Natural Lead Antithyroid Drug from Medicago sativa L. Sprouts and Its Toxic Profile in Comparison with Propylthiouracil
por: Ibrahim, Reham S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e5nhk4j351ed91fs8t60k61stv